# OVARSENSE

Development of a Liquid Biopsy Test for Ovarian cancer

What is OVARSENSE about?

Ovarian cancer is often diagnosed at an advanced stage.

In the collaborative project OVARSENSE, we aim to develop a test in which a simple blood sample (liquid biopsy) is sufficient to detect ovarian cancer and potential recurrences during and after therapy (minimal residual disease, MRD) at an earlier stage, thereby enabling more targeted treatment of ovarian cancer.

Liquid Biopsy

Early detection	Therapy response	Recurrence surveillance
Is there cancer?	Did the treatment work?	Is there residual disease?
	Is an additional therapy needed?	Is the cancer likely to recur?

This project is funded by the European Union in the field of research and innovation.

LIQOMICS

Miltenyi Biotec

Evangelisches Krankenhaus Bergisch Gladbach